文献速递乳腺癌妇科肿瘤

不同绝经激素治疗方案与乳腺癌风险

Different menopausal hormone regimens and risk of breast cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

结果显示当前单用雌激素风险略增,雌孕激素联合风险更高且随起始年龄增加,连续联合风险高于序贯,口服与经皮相似。

要点

  • 当前单用雌激素乳腺癌风险略增,OR=1.08(1.02-1.14)。
  • 当前雌孕激素联合风险更高,OR=1.77(1.69-1.85),起始年龄70+岁OR=3.59(3.30-3.91)。
  • 连续联合风险高于序贯,口服与经皮给药关联相似。

核心结论

  • 不同绝经激素治疗方案对乳腺癌风险影响差异显著,当前联合治疗风险高于单用雌激素,连续联合高于序贯。

主要发现

  • 当前单用雌激素OR=1.08(1.02-1.14);当前雌孕激素联合OR=1.77(1.69-1.85),起始年龄70+岁OR=3.59(3.30-3.91)。
  • 当前连续联合孕酮衍生物OR=2.18(1.99-2.40),睾酮衍生物OR=2.66(2.49-2.84);序贯孕酮衍生物OR=1.37(0.97-1.92),睾酮衍生物OR=1.12(0.96-1.30)。
  • 当前使用雌二醇OR=1.12(1.04-1.20),雌三醇OR=0.76(0.69-0.84),结合雌激素OR=4.47(2.67-7.48),替勃龙OR=1.68(1.51-1.87)。
  • 口服与经皮给药关联相似;既往使用与乳腺癌风险降低相关。

临床怎么用

  • 临床考虑绝经激素治疗时,应评估不同方案对乳腺癌风险的差异,尤其联合治疗及连续方案。

局限性

  • 因登记数据限制,部分混杂因素无法评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are considerable knowledge gaps concerning different estrogen and progestin formulations, regimens, and modes of administration of menopausal hormone therapy (HT) and the risk of breast cancer. Our objective was to assess the different treatment options for menopausal HT and the risk of breast cancer. PATIENTS AND METHODS: This Swedish prospective nationwide cohort study included all women who received ≥1 HT prescription during the study period 2005-2012 (290 186 ever-users), group-level matched (1 : 3) to 870 165 never-users; respectively, 6376 (2.2%) and 18 754 (2.2%) developed breast cancer. HT, ascertained from the Swedish Prescribed Drug Register, was subdivided by estrogen and progestogen formulation types, regimens (continuous versus sequential) and modes of administration (oral versus transdermal). The risk of invasive breast cancer was presented as adjusted odds ratios (OR) and 95% confidence intervals. RESULTS: Current use of estrogen-only therapy was associated with a slight excess breast cancer risk [odds ratio (OR) = 1.08 (1.02-1.14)]. The risk for current estrogen plus progestogen therapy was higher [OR = 1.77 (1.69-1.85)] and increased with higher age at initiation [OR = 3.59 (3.30-3.91) in women 70+ years]. In contrast, past use was associated with reduced breast cancer risk. Current continuous estrogen/progestin use was associated with higher risk [OR = 2.18 (1.99-2.40) for progesterone-derived; OR = 2.66 (2.49-2.84) for testosterone-derived] than sequential use [OR = 1.37 (0.97-1.92) for progesterone-derived; OR = 1.12 (0.96-1.30) for testosterone-derived]. The OR for current use was 1.12 (1.04-1.20) for estradiol, 0.76 (0.69-0.84) for estriol, 4.47 (2.67-7.48) for conjugated estrogens, and 1.68 (1.51-1.87) for tibolone. Oral and cutaneous HT showed similar associations. CONCLUSION: Different HT regimens have profoundly different effects on breast cancer risk. Because of registry limitations some confounders could not be assessed. This knowledge may guide clinical decision-making when HT is considered.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Brusselaers N, Tamimi RM, Konings P, et al. Different menopausal hormone regimens and risk of breast cancer. Ann Oncol. 2018. PMID: 29917061. doi:10.1093/annonc/mdy212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。